TG Therapeutics (TGTX) Expected to Post Earnings on Monday

Key Points

• TG Therapeutics is expected to report Q3 2026 results before Monday’s market open, November 2. Analysts forecast earnings of $0.3668 per share and revenue of $245.47 million.
• In the prior quarter, the company posted $0.05 EPS, missing estimates of $0.31, while revenue reached $240.34 million—up 70.2% year over year and above expectations.
• TGTX shares opened at $54.17, near their 52-week high, and analysts maintain a “Moderate Buy” consensus with a $63 average price target; ratings include six Buys, two Holds, and one Sell.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect TG Therapeutics to post earnings of $0.3668 per share and revenue of $245.47 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. During the same period in the prior year, the business earned $0.17 earnings per share. The firm's quarterly revenue was up 70.2% compared to the same quarter last year. On average, analysts expect TG Therapeutics to post $0.92 EPS for the current fiscal year and $2.65 EPS for the next fiscal year.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $54.17 on Monday. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. TG Therapeutics has a 1-year low of $26.76 and a 1-year high of $59.30. The company has a market cap of $8.29 billion, a PE ratio of 19.77, a price-to-earnings-growth ratio of 2.29 and a beta of 1.80. The stock's 50 day moving average price is $54.73 and its 200 day moving average price is $48.94.

Insiders Place Their Bets

In related news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares of the company's stock, valued at approximately $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 8.87% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on TGTX. Zacks Research raised TG Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 6th. Bank of America upped their price target on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a report on Friday, August 7th. HC Wainwright reiterated a "buy" rating and issued a $78.00 price objective on shares of TG Therapeutics in a research note on Tuesday, September 1st. Finally, Weiss Ratings cut shares of TG Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $63.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company's research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics' primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.